Niacinamide is currently one of the most celebrated ingredients in skincare, praised in every beauty and wellness journal for its ability to strengthen the skin barrier topically. But lately, there has been a lot of buzz about taking it orally to prevent skin cancer.

Does the science back up the hype? Yes—but with some major caveats. Let’s break down the facts and bust a few common myths based on recent clinical literature.

❌ Myth 1: Taking Vitamin B3 means you can skip the sunscreen. Fact: Oral nicotinamide does absolutely nothing to prevent sunburn. It works under the surface by preventing UV-induced immune suppression and supporting your cells’ natural DNA repair mechanisms. Think of sunscreen as your shield, and nicotinamide as your internal clean-up crew.

❌ Myth 2: Any Vitamin B3 supplement from the grocery store will work. Fact: Form matters. You need Nicotinamide (also called Niacinamide). If you accidentally purchase Nicotinic Acid (regular Niacin), you are highly likely to experience “niacin flush”—a harmless but highly uncomfortable reaction that causes your face and neck to turn bright red, itchy, and hot.

❌ Myth 3: The science is completely settled for everyone. Fact: While a landmark clinical trial showed a 23% reduction in skin cancers, and a massive 2025 study of 33,000+ veterans found up to a 54% reduction when started early, recent medical reviews remind us that the evidence isn’t one-size-fits-all. The benefits are overwhelmingly seen in high-risk individuals—specifically those who already have a history of basal cell or squamous cell carcinomas. It has not been shown to prevent melanoma.

The Bottom Line: At around $10 a month, oral nicotinamide (typically studied at 500 mg, twice daily) is an incredibly safe, accessible, and evidence-backed tool for repeat skin cancer prevention. However, the medical community agrees that “the jury is still out” on recommending it to the general population who have never had skin cancer.

If you have a history of significant sun damage, your best move is to skip the social media advice and have a direct conversation with your dermatologist.

#HealthMyths #SkincareScience #PreventativeMedicine #Dermatology #EvidenceBasedHealth #VitaminB3

Real-World Evidence vs. Meta-Analyses: The Evolving Debate on Nicotinamide for Skin Cancer Chemoprevention

The clinical utility of oral nicotinamide (NAM) for non-melanoma skin cancer (NMSC) chemoprevention remains a prime example of the tension between landmark RCT data, real-world evidence (RWE), and systematic evidence syntheses.

While the 2015 Phase 3 ONTRAC trial established a 23% reduction in new NMSCs among high-risk patients (Damian et al., NEJM), subsequent meta-analyses and recent large-scale observational data have triggered a nuanced methodological debate.

The New Evidence Landscape

1. The VA Corporate Data Warehouse Cohort (JAMA Dermatol, Nov 2025): Breglio et al. conducted a massive retrospective cohort study of 33,822 US veterans. Utilizing propensity score matching, the authors found an overall 14% reduction in skin cancer risk with oral nicotinamide (500 mg, twice daily for >30 days). Strikingly, when initiated early—after a first skin cancer diagnosis—the risk reduction rose to 54%. However, this benefit declined when treatment was initiated after multiple subsequent malignancies. Among solid organ transplant recipients (SOTRs), no overall significant risk reduction was observed, though early use trended with reduced cutaneous squamous cell carcinoma (cSCC) incidence. (Source: JAMA Dermatol. 2025;161(11):1140-1147. doi:10.1001/jamadermatol.2025.3238)

2. The Meta-Analytic View (Nutrients): Conversely, a systematic review and meta-analysis by Tosti et al. pooled data across immunocompetent and immunosuppressed cohorts, concluding that current pooled evidence is insufficient to demonstrate a statistically significant reduction in NMSC incidence (BCC RR: 0.88, 95% CI: 0.50-1.55; SCC RR: 0.81, 95% CI: 0.48-1.37). (Source: Nutrients. 2024;16(1):100. doi:10.3390/nu16010101)

3. Methodological Critique (Am J Clin Dermatol, March 2026): In a critical appraisal titled “Nicotinamide for Skin Cancer Chemoprevention: The Jury Was Out and Still Is,” Tan and Williams challenge the optimism of the 2025 VA study. They highlight significant vulnerability to residual unmeasured confounding, immortal time bias, exposure misclassification, and limited external validity given the demographic skew of the VA population. (Source: Am J Clin Dermatol. 2026;27(2):209-215. doi:10.1007/s40257-025-01005-y)

The HEOR & Clinical Takeaway

From a biological standpoint, NAM’s mechanism is compelling: it prevents UV-induced ATP depletion, replets cellular NAD+ stores, and enhances energy-dependent DNA repair pathways while mitigating UV-induced immunosuppression.

However, from an evidence-generation perspective, this timeline underscores a classic challenge:

• RCTs demonstrate efficacy under tightly controlled, high-risk conditions.

• Large-scale RWE suggests strong real-world effectiveness, particularly if introduced as an early intervention.

• Critical Appraisals & Meta-analyses remind us that retrospective observational data must be interpreted with extreme caution due to structural biases.

While the “jury is still out” on routine, widespread clinical adoption for all patient types, oral NAM remains an inexpensive (~$10/month), highly tolerable option for high-risk individuals. The key moving forward will be refining patient selection—identifying precisely who benefits most, and at what stage of their oncological history.

#Dermatology #Oncology #RealWorldEvidence #SkinCancer #ClinicalResearch #HEOR #Epidemiology

𝗪𝗵𝘆 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗗𝗲𝗽𝗲𝗻𝗱𝘀 𝗼𝗻 𝗕𝗿𝗶𝗱𝗴𝗶𝗻𝗴 “𝗪𝗲𝘁𝘄𝗮𝗿𝗲” 𝗮𝗻𝗱 𝗦𝗼𝗳𝘁𝘄𝗮𝗿𝗲.𝗧𝗵𝗲 𝗡𝗲𝘅𝘁 𝗟𝗲𝗮𝗽 𝗶𝗻 𝗔𝗜: 𝗚𝗿𝗼𝘂𝗻𝗱𝗶𝗻𝗴 𝗠𝗮𝗰𝗵𝗶𝗻𝗲 𝗟𝗲𝗮𝗿𝗻𝗶𝗻𝗴 𝗶𝗻 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗣𝗵𝘆𝘀𝗶𝗰𝘀. 𝗙𝗿𝗼𝗺 𝗢𝗯𝘀𝗲𝗿𝘃𝗮𝘁𝗶𝗼𝗻 𝘁𝗼 𝗖𝗼𝗻𝘁𝗿𝗼𝗹: 𝗧𝗵𝗲 𝗡𝗲𝘄 𝗘𝗿𝗮 𝗼𝗳 𝗖𝗼𝗺𝗽𝘂𝘁𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗡𝗲𝘂𝗿𝗼𝘀𝗰𝗶𝗲𝗻𝗰𝗲. The future of AI and biotech isn’t just about collecting more data; it’s about building better models of the underlying “physics” of the system. We are seeing a significant shift where classical differential equations are converging with modern machine learning. This hybrid approach is set to redefine how we process neural signals and design cognitive interventions.

Currently, the hierarchy of Ordinary Ddifferential Equations (ODE), Partial DE, and Stochastic DE models allows us to map everything from deterministic whole-brain networks to stochastic membrane fluctuations. This multiscale approach is vital because it ensures that our models remain grounded in biological reality while benefiting from the computational power of ML-driven inference.

One of the most exciting “open challenges” in this field is the move toward control-oriented formulations. Once we can accurately model neural dynamics using these mathematical frameworks, we can begin to design systems that don’t just observe the brain but interact with it in real-time to correct pathological states or enhance performance.

This convergence has massive implications for the “Global Economy” of health and technology. By integrating kinetic variables and mean-field equations with neural field theory, we are creating a standardized language for computational neuroscience that can be scaled across research and industrial applications.

I am particularly focused on how these models will tackle multiscale inference in the coming years. As we refine our numerical and computational approaches for stochastic systems, the gap between “wetware” (the brain) and “software” (AI) will continue to shrink. The math may be complex, but the potential for innovation is limitless.

𝐎𝐫𝐝𝐞𝐫 𝐟𝐫𝐨𝐦 𝐂𝐡𝐚𝐨𝐬: 𝐇𝐨𝐰 𝐑𝐚𝐧𝐝𝐨𝐦𝐧𝐞𝐬𝐬 𝐃𝐫𝐢𝐯𝐞𝐬 𝐍𝐞𝐮𝐫𝐚𝐥 𝐋𝐞𝐚𝐫𝐧𝐢𝐧𝐠 𝐚𝐧𝐝 𝐏𝐥𝐚𝐬𝐭𝐢𝐜𝐢𝐭𝐲. 𝐖𝐡𝐲 “𝐍𝐨𝐢𝐬𝐞” 𝐢𝐬 𝐭𝐡𝐞 𝐒𝐞𝐜𝐫𝐞𝐭 𝐒𝐚𝐮𝐜𝐞 𝐨𝐟 𝐇𝐮𝐦𝐚𝐧 𝐈𝐧𝐭𝐞𝐥𝐥𝐢𝐠𝐞𝐧𝐜𝐞. 𝐃𝐞𝐜𝐨𝐝𝐢𝐧𝐠 𝐔𝐧𝐜𝐞𝐫𝐭𝐚𝐢𝐧𝐭𝐲: 𝐔𝐬𝐢𝐧𝐠 𝐒𝐭𝐨𝐜𝐡𝐚𝐬𝐭𝐢𝐜 𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧𝐬 𝐭𝐨 𝐔𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝 𝐭𝐡𝐞 𝐁𝐫𝐚𝐢𝐧’𝐬 𝐂𝐡𝐚𝐨𝐬.

In most engineering disciplines, “noise” is an enemy to be filtered out or minimized. However, in the human brain, noise is a fundamental feature of the architecture. My recent work explores how stochastic neural dynamics—the inherent randomness in how our neurons fire—actually enables the complexity and adaptability we call intelligence.

When we model the brain, we often start with deterministic equations (ODEs) to map out the basic structure. But to capture the “vibe” of real biological systems, we have to embrace Stochastic Differential Equations (SDEs). These models help us understand the irregular spike trains and synaptic plasticity that allow the brain to learn and reorganize itself.

By focusing on the evolution of population densities through Fokker-Planck equations, we can see how individual “random” actions at the cellular level emerge as organized patterns at the mesoscopic level. It is a fascinating look at how order arises from apparent chaos, providing a mathematical lens for the study of neurovariability.

For those of us working at the intersection of data science and biology, this approach is a game-changer for neural data analysis. It allows us to move beyond simple signal averaging and instead infer the “latent dynamics”—the hidden rules governing brain activity—even when the recordings are incredibly noisy.

The goal is to move toward a unified toolset for multiscale modeling. Whether we are looking at single-cell excitability or whole-brain activity, the hierarchy of ODE, PDE, and SDE models provides the bridge. Embracing the math of uncertainty is ultimately what will lead us to a deeper understanding of human cognition.